JP2004537554A - 置換されたピペラジン化合物および脂肪酸酸化インヒビターとしてのその使用 - Google Patents

置換されたピペラジン化合物および脂肪酸酸化インヒビターとしてのその使用 Download PDF

Info

Publication number
JP2004537554A
JP2004537554A JP2003513970A JP2003513970A JP2004537554A JP 2004537554 A JP2004537554 A JP 2004537554A JP 2003513970 A JP2003513970 A JP 2003513970A JP 2003513970 A JP2003513970 A JP 2003513970A JP 2004537554 A JP2004537554 A JP 2004537554A
Authority
JP
Japan
Prior art keywords
compound
formula
optionally substituted
phenyl
yloxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP2003513970A
Other languages
English (en)
Japanese (ja)
Other versions
JP2004537554A5 (enExample
Inventor
パラブハ・イブラヒム
ケビン・シェンク
エルファティー・エルツェイン
ヴェンカタ・パレ
ジェフ・ザブロッキー
ケネス・レーダー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Gilead Palo Alto Inc
Original Assignee
CV Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by CV Therapeutics Inc filed Critical CV Therapeutics Inc
Publication of JP2004537554A publication Critical patent/JP2004537554A/ja
Publication of JP2004537554A5 publication Critical patent/JP2004537554A5/ja
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
    • C07D263/56—Benzoxazoles; Hydrogenated benzoxazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D263/57—Aryl or substituted aryl radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/64—Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Transplantation (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Lubricants (AREA)
  • Pyridine Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Emulsifying, Dispersing, Foam-Producing Or Wetting Agents (AREA)
  • Paper (AREA)
  • Hydrogenated Pyridines (AREA)
JP2003513970A 2001-07-19 2002-07-18 置換されたピペラジン化合物および脂肪酸酸化インヒビターとしてのその使用 Ceased JP2004537554A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US30662101P 2001-07-19 2001-07-19
PCT/US2002/022897 WO2003008411A1 (en) 2001-07-19 2002-07-18 Substituted piperazine compounds and their use as fatty acid oxidation inhibitors

Publications (2)

Publication Number Publication Date
JP2004537554A true JP2004537554A (ja) 2004-12-16
JP2004537554A5 JP2004537554A5 (enExample) 2006-01-05

Family

ID=23186103

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003513970A Ceased JP2004537554A (ja) 2001-07-19 2002-07-18 置換されたピペラジン化合物および脂肪酸酸化インヒビターとしてのその使用

Country Status (21)

Country Link
US (1) US6930111B2 (enExample)
EP (1) EP1406898B1 (enExample)
JP (1) JP2004537554A (enExample)
KR (1) KR100919141B1 (enExample)
CN (1) CN1533388A (enExample)
AT (1) ATE292633T1 (enExample)
AU (1) AU2008202958A1 (enExample)
CA (1) CA2454059A1 (enExample)
DE (1) DE60203623T2 (enExample)
DK (1) DK1406898T3 (enExample)
ES (1) ES2236557T3 (enExample)
HU (1) HUP0402088A3 (enExample)
IL (1) IL159897A0 (enExample)
MX (1) MXPA04000565A (enExample)
NO (1) NO327635B1 (enExample)
NZ (1) NZ530705A (enExample)
PL (1) PL368529A1 (enExample)
PT (1) PT1406898E (enExample)
RU (1) RU2300533C2 (enExample)
WO (1) WO2003008411A1 (enExample)
ZA (1) ZA200400404B (enExample)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005532331A (ja) * 2002-05-21 2005-10-27 シーブイ・セラピューティクス・インコーポレイテッド 糖尿病を処置する方法
JP2006515891A (ja) * 2003-01-17 2006-06-08 シーブイ・セラピューティクス・インコーポレイテッド 循環器疾患の処置に有効な置換ヘテロ環化合物
JP2006516036A (ja) * 2003-01-17 2006-06-15 シーブイ・セラピューティクス・インコーポレイテッド 置換ヘテロ環式化合物

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8822473B2 (en) * 2002-05-21 2014-09-02 Gilead Sciences, Inc. Method of treating diabetes
WO2004014881A2 (en) 2002-08-09 2004-02-19 Astra Zeneca Ab '1,2,4'oxadiazoles as modulators of metabotropic glutamate receptor-5
CN1691944A (zh) * 2002-08-09 2005-11-02 阿斯利康(瑞典)有限公司 作为代谢型谷氨酸受体－5调节剂的噁二唑
AU2003264018A1 (en) 2002-08-09 2004-02-25 Astrazeneca Ab Compounds having an activity at metabotropic glutamate receptors
ATE365737T1 (de) * 2002-12-05 2007-07-15 Cv Therapeutics Inc Substituierte piperazinverbindungen undderen verwendung als fettsuureoxidationsinhibitoren
EP1806346B1 (en) * 2002-12-05 2009-07-22 Cv Therapeutics, Inc. Substituted piperazine compounds and their use as fatty acid oxidation inhibitors
NZ541069A (en) 2003-01-03 2008-09-26 Cv Therapeutics Inc Piperazine derivatives as fatty acid oxidation inhibitors
CA2530376A1 (en) * 2003-06-23 2005-01-06 Cv Therapeutics, Inc. Urea derivatives of piperazines and piperidines as fatty acid oxidation inhibitors
CA2550257A1 (en) 2003-12-18 2005-07-07 Cv Therapeutics, Inc. 1-akan-2-ol substituted piperazine and piperidine compounds
JP2007517550A (ja) 2004-01-02 2007-07-05 アドヴァンスド カーディオヴァスキュラー システムズ， インコーポレイテッド 高比重リポ蛋白をコーティングした医療デバイス
US7271169B2 (en) * 2004-09-08 2007-09-18 Cv Therapeutics, Inc. Substituted heterocyclic compounds
CN101541331A (zh) 2006-08-24 2009-09-23 沃克哈特研究中心 具有抗微生物活性的新颖大环内酯和酮内酯
US8088920B2 (en) * 2008-03-31 2012-01-03 Hoffmann-La Roche Inc. 3-trifluoromethyl-pyrazine-2-carboxylic acid amide derivatives as HDL-cholesterol raising agents
ES2617873T3 (es) * 2008-10-10 2017-06-20 Vm Discovery, Inc. Composiciones y métodos para tratar trastornos de alcoholismo, dolor y otras enfermedades
MX2011012140A (es) * 2009-05-14 2012-02-28 Gilead Sciences Inc Ranolazina para el tratamiento de problemas del snc.
WO2011115150A1 (ja) * 2010-03-18 2011-09-22 興和株式会社 ベンゾチアジン化合物の製造方法
CN111285819A (zh) * 2018-12-07 2020-06-16 江苏恩华药业股份有限公司 一种苯并噁唑类化合物及其应用
WO2023023995A1 (zh) * 2021-08-25 2023-03-02 苏州大学 一种防治心肌缺血后心功能衰竭的药物及其应用

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5522686A (en) * 1978-08-01 1980-02-18 Schering Ag Polyalkoxyphenylpyrrolidone*its manufacture and medicine containing it and having vasodilating and hypotensive action
JPS6137765A (ja) * 1984-07-19 1986-02-22 サンド・アクチエンゲゼルシヤフト ３‐アミノプロポキシアリール誘導体
US4723014A (en) * 1986-11-19 1988-02-02 Warner-Lambert Company Process for the preparation of 2-substituted-1,4-dihydropyridines
DE3723648A1 (de) * 1987-07-17 1989-01-26 Sandoz Ag Indol-derivate, ihre herstellung und sie enthaltende arzneimittel
JPH02268162A (ja) * 1989-04-10 1990-11-01 Fujisawa Pharmaceut Co Ltd ジフェニルピリジン誘導体
JPH03101662A (ja) * 1988-10-06 1991-04-26 Mitsui Toatsu Chem Inc 新規複素環化合物およびそれを有効成分として含有する製癌剤効果増強剤
JPH06256277A (ja) * 1992-12-22 1994-09-13 Eli Lilly & Co Ａｉｄｓの処置のために有用なｈｉｖ−プロテアーゼ阻害剤
JP2004511559A (ja) * 2000-10-20 2004-04-15 アストラゼネカ　アクチボラグ ３，８−ジアザビシクロ［３．２．１］オクタン及び心不整脈の治療におけるその使用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1133989A (en) * 1964-12-08 1968-11-20 Chugai Pharmaceutical Co Ltd Theophylline derivatives, their salts and process for preparing the same
US4567264A (en) * 1983-05-18 1986-01-28 Syntex (U.S.A.) Inc. Cardioselective aryloxy- and arylthio- hydroxypropylene-piperazinyl acetanilides which affect calcium entry
EP0938480A1 (en) * 1996-11-14 1999-09-01 American Home Products Corporation Substituted tetrahydro-1,3,5-triazin-2 1h]-thiones as anti-atherosclerotic agents
BR0013943A (pt) * 1999-09-13 2002-05-14 American Home Prod Conjugados de glicopiranosìdeos de 2-(4-hidróxi-fenil)-1-[4-(2-amin-1-il-etóxi)-benzil]-1h-indo l-5-óis
SE9904765D0 (sv) * 1999-12-23 1999-12-23 Astra Ab Pharmaceutically-useful compounds
WO2001062711A2 (en) * 2000-02-22 2001-08-30 Cv Therapeutics, Inc. Substituted alkylene diamine compounds
AU2001238590A1 (en) * 2000-02-22 2001-09-03 Cv Therapeutics, Inc. Substituted piperazine compounds
US6451798B2 (en) * 2000-02-22 2002-09-17 Cv Therapeutics, Inc. Substituted alkyl piperazine derivatives
US6552023B2 (en) * 2000-02-22 2003-04-22 Cv Therapeutics, Inc. Aralkyl substituted piperazine compounds
NZ520782A (en) * 2000-02-22 2004-03-26 Cv Therapeutics Inc Substituted piperazine compounds that are partial fatty acid oxidation inhibitors
US6573264B1 (en) * 2000-10-23 2003-06-03 Cv Therapeutics, Inc. Heteroaryl alkyl piperazine derivatives

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5522686A (en) * 1978-08-01 1980-02-18 Schering Ag Polyalkoxyphenylpyrrolidone*its manufacture and medicine containing it and having vasodilating and hypotensive action
JPS6137765A (ja) * 1984-07-19 1986-02-22 サンド・アクチエンゲゼルシヤフト ３‐アミノプロポキシアリール誘導体
US4723014A (en) * 1986-11-19 1988-02-02 Warner-Lambert Company Process for the preparation of 2-substituted-1,4-dihydropyridines
DE3723648A1 (de) * 1987-07-17 1989-01-26 Sandoz Ag Indol-derivate, ihre herstellung und sie enthaltende arzneimittel
JPH03101662A (ja) * 1988-10-06 1991-04-26 Mitsui Toatsu Chem Inc 新規複素環化合物およびそれを有効成分として含有する製癌剤効果増強剤
JPH02268162A (ja) * 1989-04-10 1990-11-01 Fujisawa Pharmaceut Co Ltd ジフェニルピリジン誘導体
JPH06256277A (ja) * 1992-12-22 1994-09-13 Eli Lilly & Co Ａｉｄｓの処置のために有用なｈｉｖ−プロテアーゼ阻害剤
JP2004511559A (ja) * 2000-10-20 2004-04-15 アストラゼネカ　アクチボラグ ３，８−ジアザビシクロ［３．２．１］オクタン及び心不整脈の治療におけるその使用

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005532331A (ja) * 2002-05-21 2005-10-27 シーブイ・セラピューティクス・インコーポレイテッド 糖尿病を処置する方法
JP2006515891A (ja) * 2003-01-17 2006-06-08 シーブイ・セラピューティクス・インコーポレイテッド 循環器疾患の処置に有効な置換ヘテロ環化合物
JP2006516036A (ja) * 2003-01-17 2006-06-15 シーブイ・セラピューティクス・インコーポレイテッド 置換ヘテロ環式化合物

Also Published As

Publication number Publication date
EP1406898B1 (en) 2005-04-06
WO2003008411A1 (en) 2003-01-30
NO327635B1 (no) 2009-09-07
EP1406898A1 (en) 2004-04-14
NO20040234L (no) 2004-03-18
US6930111B2 (en) 2005-08-16
DK1406898T3 (da) 2005-05-30
IL159897A0 (en) 2004-06-20
DE60203623D1 (de) 2005-05-12
RU2300533C2 (ru) 2007-06-10
CN1533388A (zh) 2004-09-29
CA2454059A1 (en) 2003-01-30
MXPA04000565A (es) 2005-06-17
AU2008202958A1 (en) 2008-07-31
AU2002322527A2 (en) 2003-03-03
PL368529A1 (en) 2005-04-04
AU2002322527B2 (en) 2008-04-17
NZ530705A (en) 2005-08-26
HUP0402088A2 (hu) 2005-02-28
ES2236557T3 (es) 2005-07-16
US20030181352A1 (en) 2003-09-25
KR20040029374A (ko) 2004-04-06
RU2004104951A (ru) 2005-06-27
HUP0402088A3 (en) 2010-03-29
HK1064374A1 (en) 2005-01-28
KR100919141B1 (ko) 2009-09-25
PT1406898E (pt) 2005-08-31
ATE292633T1 (de) 2005-04-15
DE60203623T2 (de) 2006-01-19
ZA200400404B (en) 2004-10-14

Similar Documents

Publication Publication Date Title
US6930111B2 (en) Substituted heterocyclic compounds
US7001909B2 (en) Substituted heterocyclic compounds
US20040186109A1 (en) Substituted heterocyclic compounds
US7056924B2 (en) Substituted heterocyclic compounds
AU2002322527C1 (en) Substituted piperazine compounds and their use as fatty acid oxidation inhibitors
AU2002322527A1 (en) Substituted piperazine compounds and their use as fatty acid oxidation inhibitors
HK1064374B (en) Substituted piperazine compounds and their use as fatty acid oxidation inhibitors
US7271169B2 (en) Substituted heterocyclic compounds
HK1083492A1 (en) Substituted piperazine compounds and their use as fatty acid oxidation inhibitors
HK1083492B (en) Substituted piperazine compounds and their use as fatty acid oxidation inhibitors

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20050531

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20050531

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20081224

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20090324

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20090331

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20090421

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20090428

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090525

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20090917

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20091020

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20100104

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100108

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20100225

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20100316

A045 Written measure of dismissal of application [lapsed due to lack of payment]

Free format text: JAPANESE INTERMEDIATE CODE: A045

Effective date: 20100727